1. Home
  2. REPL vs RPAY Comparison

REPL vs RPAY Comparison

Compare REPL & RPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • RPAY
  • Stock Information
  • Founded
  • REPL 2015
  • RPAY 2006
  • Country
  • REPL United States
  • RPAY United States
  • Employees
  • REPL N/A
  • RPAY N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • RPAY Business Services
  • Sector
  • REPL Health Care
  • RPAY Consumer Discretionary
  • Exchange
  • REPL Nasdaq
  • RPAY Nasdaq
  • Market Cap
  • REPL 780.3M
  • RPAY 665.4M
  • IPO Year
  • REPL 2018
  • RPAY N/A
  • Fundamental
  • Price
  • REPL $11.85
  • RPAY $7.48
  • Analyst Decision
  • REPL Strong Buy
  • RPAY Strong Buy
  • Analyst Count
  • REPL 6
  • RPAY 6
  • Target Price
  • REPL $17.50
  • RPAY $12.33
  • AVG Volume (30 Days)
  • REPL 818.5K
  • RPAY 541.0K
  • Earning Date
  • REPL 02-06-2025
  • RPAY 02-27-2025
  • Dividend Yield
  • REPL N/A
  • RPAY N/A
  • EPS Growth
  • REPL N/A
  • RPAY N/A
  • EPS
  • REPL N/A
  • RPAY N/A
  • Revenue
  • REPL N/A
  • RPAY $310,758,000.00
  • Revenue This Year
  • REPL N/A
  • RPAY $9.03
  • Revenue Next Year
  • REPL $300.41
  • RPAY $5.59
  • P/E Ratio
  • REPL N/A
  • RPAY N/A
  • Revenue Growth
  • REPL N/A
  • RPAY 5.95
  • 52 Week Low
  • REPL $4.92
  • RPAY $7.15
  • 52 Week High
  • REPL $17.00
  • RPAY $11.27
  • Technical
  • Relative Strength Index (RSI)
  • REPL 51.79
  • RPAY 43.43
  • Support Level
  • REPL $10.05
  • RPAY $7.34
  • Resistance Level
  • REPL $11.20
  • RPAY $7.60
  • Average True Range (ATR)
  • REPL 0.92
  • RPAY 0.20
  • MACD
  • REPL -0.08
  • RPAY -0.00
  • Stochastic Oscillator
  • REPL 51.97
  • RPAY 46.48

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

About RPAY Repay Holdings Corporation

Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segment, Consumer Payment and Business Payments.

Share on Social Networks: